InMed Pharmaceuticals Inc. — Form 8-K
Filed November 16, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
On November 6, 2026, Mentari Therapeutics (pre-merger) completed a reverse recapitalization merger with InMed Pharmaceuticals Inc., with InMed assuming Mentari's name and leadership. Immediately prior to closing, Mentari raised $490M gross ($290M + $200M in two tranches) from investors via preferred stock and pre-funded warrants at $1.8928 and $2.8923 per share respectively, including $52.7M principal+accrued interest conversion of Mentari's $50M convertible note to Fairmount. Post-merger, former Mentari shareholders own ~99% of combined company on fully diluted basis; former InMed shareholders own ~1%. The combined company retains Mentari's migraine-focused pipeline (MT-001 through MT-005 antibodies).
Why this rating
Transformational for Mentari (pre-$3M market cap): $490M gross capital injection represents massive relative size; establishes public trading market; enables multi-year runway (~2029). Merger itself non-dilutive to Mentari holders via favorable exchange ratio. However, pre-merger Mentari shareholders diluted ~74% by financing investors; going-concern risk eliminated but capital efficiency diminished.
Tradability signal
NO TRADE
No trade: positive news with no measurable pre-read move — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: -0.43% over 4 hrs, n=488). (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
at our read · unknown $15.56 | +10 min · unknown $15.56 ▲ 0.00% | +30 min · unknown $15.56 ▲ 0.00% | +1 hr · unknown $15.56 ▲ 0.00% | +4 hrs · unknown $15.56 ▲ 0.00% |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 16, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.